The drug GG918 has been specifically developed for overcomcould be achieved with acceptable toxicity. [8] [9] [10] However, this ing MDR phenotype and is now in use in clinical trials. In this modulator significantly increased the area under the curve of study, the effects of GG918 on leukemic cell were investigated the co-administrated cytostatic drugs, 9-11 and therefore using a 3 day MTT assay. Results showed that, in a highly increased their toxicity. 12 not increase DNR toxicity in four of these eight cases, but was More interestingly, GG918 had little effect on the blood and more efficient in one other MDR1(؉) case. In conclusion, the tissue levels of doxorubicin when both drugs were co-admin-DNR sensitivity of the majority of the fresh AML samples istrated in mice. 12 For these reasons, we decided to test this expressing P-gp could be modulated in vitro by 1 M of GG918.
Introduction

Materials and methods
Multidrug resistant (MDR) phenotype, present from the outset Cells lines of leukemia or arising during chemotherapy, is associated with treatment failure in acute leukemia. 1, 2 Typical MDR is HL60, a human promyelocytic leukemia cell line; HL60/DNR, related to the overexpression of the MDR1 gene, which encoa P-gp(+) subline of HL60 resistant to daunorubicin (gifts from des a 170 kDa P-glycoprotein (P-gp) that acts as a transmem-F Lacombe, Bordeaux, France); K562, a human erythroleukebrane drug efflux pump. 3 This efflux can be inhibited by many mia cell line, and K562/Adr, a MDR subline of K562 resistant non-cytotoxic compounds, but until now the ability to reverse to adriamycin (gifts from BI Sikic, Stanford, CA, USA) were this drug resistance induced by the MDR phenotype has not used as positive and negative controls for MDR1 phenotype. been demonstrated in vivo. Another drug efflux pump, the Two K562 sublines resistant to different concentrations of multidrug resistance protein (MRP), was more recently homoharringtonine (HHT): K562/HHT100 (MRP+, MDR1+), described by Cole et al 4 in a lung cancer cell line, and is also and K562/HHT200 (MRP+, MDR1++) developed in our labable to mimic the MDR phenotype (induced by P-gp) after oratory, 14 and A549, a lung adenocarcinoma cell line expresscDNA transfection into sensitive cells. 5 ing spontaneously high levels of MRP but no P-gp (gift from Verapamil, the first P-gp modulator described in 1981, 6 was S Chevillard, Institut Curie, Paris, France), were used for testextensively tested in association with doxorubicin to treat ing the effect of GG918 on MRP phenotype. All cell lines were clinically refractory cancers, but phase I and II trials demontested for in vitro sensitivity during exponential growth, and strated that the cardio-vascular toxicity is dose-limiting at were routinely cultivated in RPMI medium and 10% fetal calf serum concentrations of 1-2 M, while in most in vitro models serum ('growth medium') (± cytostatic). for MDR, concentrations of 6-10 M are required for full inhibition of P-gp. 7 Phases I-II with cyclosporin A (CsA), a potent P-gp modulator in vitro, demonstrated that serum levels of 2-Fresh leukemic cells from patients 4 Rhodamine and DNR uptake by gradient density, and leukemic cells represented at least 80% of the cells when tested. We described this technique extensively elsewhere. 16 Briefly, 10 6 cells were incubated at 37°C in presence of 0.2 g/ml of rhodamine 1,2,3 (rho) ± GG918 (0.1-1 M) or 10 M of verapamil as reference. After 1 h, cells were washed twice and Growth inhibition assay passed through a cytometer (Facsort; Becton Dickinson, Pont de Clay, France), the signal of FL1 was selected, and the Cell growth inhibition was determined by plating 2 × 10 5 cells uptake variation was calculated by the variation of the mean in 200 l growth medium containing serial dilutions (10 nM of fluorescence (rho + modulator/rho). to 30 M) of the cytostatic drug in 96-well microtiter plates.
On some occasions, DNR was used instead of rhodamine. Each concentration of the drug (daunorubicin, mitoxantrone, Cells were incubated for 1 h with 10 −6 M DNR ± modulators idarubicin) was repeated in six wells. The experiences were at 37°C, then washed and passed through the cytometer. The repeated three times, and the mean ± standard deviation was FL2 channel displayed the histogram of control cells (without calculated. GG918 (1 M) (gift from F Hyafil, Glaxo France DNR) for autofluorescence, and the signal given by the sponResearch Lab, Les Ulis, France) or 10 M of verapamil (Knoll taneous fluorescence of DNR taken up by the cells. The effect France, Levallois-Perret, France) were added into the culture of modulators was calculated as for rhodamine (DNR + medium. After incubation for 3 days at 37°C with 5% CO 2 , modulator/DNR). cell viability was determined using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Briefly, 20 l of MTT (5 mg/ml in PBS) was added to each well folStatistics lowed by 5 h of incubation. The medium and MTT were then removed from the wells, and formazan crystals were dissolved Student's t-test was used for comparison of IC 50 /DNR. For in 200 l of DMSO. The absorbance was recorded in a modulation of drug sensitivity and rhodamine uptake, a simmicroplate reader at the wavelength of 550 nm. The effect of ple regression curve was drawn. For evaluation of the effect drug on growth inhibition could be assessed as:
of modulators on rhodamine uptake, the Kosmogorov-Smirnov test allowed us to set the threshold for significant modu-% of growth inhibition lation at 1.5 for the ratio of mean fluorescence of dye + modulator/dye alone: above this value, the Kosmogo-= 1 − absorbance of drug-treated cells absorbance of untreated cells × 100 rov-Smirnov test was significant (P Ͻ 0.05).
The 50% inhibitory concentration (IC 50 ) was determined as the drug concentration which results in a 50% of growth inhiResults bition. When IC 50 was very low (Ͻ50 nM), the curve did not allow calculation of the exact value of IC 50 for DNR alone
In vitro intrinsic cytotoxicity of GG918 in vitro in and for modulators: in these cases, an IC 50 /DNR of 50 nM was leukemic cell lines used for calculation.
To test the contribution of serum in the modulator effect The intrinsic IC 50 of GG918 for HL60/DNR and K562/Adr was observed, variable concentrations of pooled human AB serum 50 M for both cell lines. It was not different to the IC 50 (from the blood bank, Hô tel-Dieu) was added to the incuobserved in sensitive parental cell lines. bation medium (10-50%; 100% gave unreadable results with MTT due to the optical density of the pure serum).
Effect of GG918 in vitro on leukemic cell lines (Table 1 RT-PCR RI DNR = 81) than its parental cell line HL60, co-incubation with 0.1 M and 1.0 M of GG918 40-and 44-fold (residual RI: 2.1 and 1.8); respectively ( Figure 1 ). For the K562/Adr cell mdr1 mRNA semi-quantification was tested as described extensively elsewhere. 15 Briefly, cDNA was synthesized with line (RI DNR = 230), co-incubation with 0.1 M and 1.0 M of GG918 resulted in an increase in sensitization by 57-and 85-MMLV reverse transcriptase (GIBCO/BRL, Cergy-Pontoise, France). PCR of 30 cycles and 25 cycles, respectively, were fold to DNR (residual RI: 3.8 and 2.7), respectively. Co-incubation with very low concentration (0.01 M) of GG918 had carried out with one radioactive nucleotide to amplify the MDR1 and ␤2m cDNAs, respectively. PCR products were sepa weak effect of sensitization for both HL60/DNR and K562/Adr cell lines (1.3 and 1.5, respectively). Compared to arated on 2% agarose gel and stained with ethidium bromide. Bands corresponding to each specific PCR product were verapamil (10 M), which could increase by 7-and 17-fold the cytotoxic effect of daunorubicin in HL60/DNR and excised from the gels and the incorporated radioactivity was determined by liquid scintillation counting. The results were K562/Adr cell lines (residual RI: 11.6 and 13.5), GG918 showed higher sensitization potency for a hundred times normalized with the relative quantity of ␤2m. According to our previous studies, a result was considered positive (+) when lower concentration of modulator. When HL60/DNR was exposed to 10 −5 M (85% survival) and 10 −6 M (100% survival) of DNR, the addition of 0.025 M and 0.1 M of GG918, respectively, was enough to potentiate fully the effect of the cytostatic drug (Figure 2) .
To test the effect of GG918 on resistant cell lines coexpressing MRP and MDR1 genes, we exposed two K562 sublines with various expression levels of these two genes to DNR ± GG918: in K562/HHT100 (MRP+, MDR1+, RI DNR : 5) and in K562/HHT200 (MRP+, MDR1++, RI DNR : 36), the addition of 1 M of GG918 rendered the cell lines fully sensitive to DNR. The DNR sensitivity of A549, a lung tumor cell line spontaneously expressing MRP but no P-gp, was not modified by the addition of 1 M of GG918 (data not shown).
Figure 1
Dose-response curve of HL60/DNR to DNR determined by MTT assay, with 0.1 and 1 M of GG918, and 10 M of verapamil.
Resistance to idarubicin (IDA):
A complete reversion of resistance to idarubicin could be obtained with 1 M of GG918 in HL60/DNR cells (RI IDA : 10), and a residual resistance index of 2.4 was observed with K562/Adr cells (RI IDA : 21). These results were superior to those obtained with 10 M of verapamil (residual RI: 1.7 for HL60/DNR and 3.8 for K562/Adr).
Resistance to mitoxantrone (MITOX):
A complete reversion of resistance to mitoxantrone of the K562/Adr cells (RI MITOX : 19) could be obtained with 100 nM of GG918, and the reversion was nearly complete (residual RI: 1.5) with HL60/DNR cells (RI MITOX : 88).
Effect of human serum ( Table 2) :
The pooled human AB serum increased the IC 50 of DNR alone in K562 (×2 when
Figure 2
Effect of increasing concentrations of GG918 on HL60/DNR cell survival in the presence of 10 −5 M or 10 −6 M of DNR.
50% serum was added) and K562/Adr (×4 with 30%, ×5.5 
Effect of GG918 on in vitro DNR sensitivity of fresh leukemic cells
Discussion
DNR sensitivity and mdr 1 status
We described here the in vitro effect of GG918, a new potent MDR modulator with low toxicity, on drug sensitivity of leuData are presented in Table 3 . The IC 50 /DNR varied from less than 50 nM (set at 50 M for calculation) to 4500 nM in the kemic cells. This acridone carboxamide derivative has been selected from a chemical program aimed at identifying an 27 cases tested.
No differences were observed in in vitro DNR sensitivity optimized inhibitor of P-gp. 12 We confirmed here the in vitro potency of this compound for reversing the resistance of two between newly diagnosed acute leukemias and pretreated patients (P = 0.22).
leukemic cell lines, K562/Adr and HL60/DNR (both expressing high levels of MDR), to DNR, idarubicin and mitoxanEleven out of 26 patients expressed MDR1 gene (43%). These patients exhibited higher DNR IC 50 (861 ± 1284 nM) trone. Low levels of GG918 (100 nM, 500 times below the intrinsic toxicity) were much more efficient for reversing DNR than the patients negative for mdr1 (Ͻ187 ± 246 nM) (P = 0.05) (Figure 3) . resistance than high dose verapamil. With GG918, we also observed a complete (or nearly complete) reversion of resistSix patients had a very low IC 50 /DNR (Ͻ50 nM): all were negative for mdr1, and modulation could not be tested.
ance to idarubicin in the leukemic cell lines, despite the fact that these P-gp(+) cells lines were considered to exhibit less cross-resistance to idarubicin than to other anthracyclines. 17 When K562/HHT sublines, expressing both MDR1 and MRP
Modulations of DNR sensitivity and rhodamine uptake genes at moderate levels, were tested, GG918 was able to restore full sensitivity to DNR. The lack of effect of GG918 When the results of the two techniques could be compared (17 cases), a good correlation (r = 0.8, P = 0.001) was found on the DNR sensitivity of the A549 cell line, expressing only MRP, suggested the dominance of P-gp efflux in the MDR between the modulation of DNR sensitivity and the modification of rhodamine uptake by the GG918, and similarly phenotypes of the K562/HHT100 and 200 cell lines, coexpressing both genes and fully sensitized by GG918. These between MDR1 expression and rhodamine and/or DNR efflux (P = 0.004 and P = 0.001, respectively) (Figure 4) . data are encouraging for the clinical use of such a modulator in AML, often expressing both resistance genes. 15 Eight patients showed a decrease of IC 50 /DNR by at least 2-fold (/2 to /3.1) in the presence of 1 M GG918 (Nos 13, 14, den Ouden et al 13 described a powerful reversing effect of GG918 (GF120918) in the 8226/Dox myeloma cell lines, with 18, 19, 22, 25, 26, 27) , including those with the highest resistance to DNR. Seven of these eight patients were tested for a concentration between 0.5 and 2 M, but noticed decreased activity in the presence of fetal calf serum. We observed the MDR1 expression and were found to be positive. When tested, rhodamine or DNR (case No. 22) uptake was also same decrease of activity with increasing concentration of human AB serum. They observed a significant reversion of increased after co-exposure to GG918 ( Figure 5) .
In four of these eight cases, 10 M of verapamil had no rhodamine efflux with 2 M of GG918 in 11/23 P-gp-positive Table 3 Effect of GG918 and verapamil on DNR sensitivity and rhodamine uptake of fresh acute leukemic cells modulators, and depends on the protein binding of the compound.
The level of drug resistance observed in fresh acute leukemia samples was usually far lower than that observed in highly resistant cell lines: the maximum IC 50 for DNR noted in clinical samples of this study was much lower than the IC 50 of K562/Adr. On the other hand, the same range of resistance to DNR (IC 50 = 1-4 M) was noticed in the most resistant clinical samples and in the less resistant cell line (K562/HHT100), which exhibited a 7-fold resistance to DNR. We thus conclude that this type of cell line should be used for reference in the measurement of MDR phenotype in clinical samples. 15 The IC 50 of DNR observed in clinical specimens varied widely, and could not be predicted by the clinical status: the same range of DNR sensitivity was observed in untreated and in relapsing/refractory cases. The mean IC 50 observed here was four times higher than those reported by Baines et al, 19 who tested mainly de novo untreated AML. We have selected ondary leukemia: only six cases were de novo AML, including three AML5. The cases expressing MDR1 gene exhibited samples of AML, and in two out of the six P-gp-positive myehigher DNR IC 50 compared to the others, and showed the loma samples tested.
highest potency for modulation with GG918. Surprisingly, two When human serum was added to the medium (above cases expressed MDR1 but did not have high DNR IC 50 and 20%), the binding of DNR to plasma proteins increased the could not be modulated; this could be due to the presence of IC 50 of this drug in the K562/Adr cell line. As reported here, a non-functional P-gp, as observed in MRK16(+) but CD34-in the same circumstances the amount of GG918 had to be negative AML cases in the literature. 20, 21 Unfortunately, this increased to 1 M to observe full reversion. This phenomenon antigen was not prospectively tested in this study. The rhodahas previously been observed by Ludescher et al 18 for all mine uptake was mainly in accordance with IC 50 DNR, but ating leukemic cells during a clinical trial with such a compound in AML. The relatively low DNR sensitization obtained either by GG918 or verapamil in the most resistant clinical samples could reflect the involvement of other mechanisms of resistance such as LRP, a vault protein, the expression of which is increased in many resistant cell lines, 24 or predominant overexpression of MRP, or resistance to apoptosis. 25 In several cases, the decrease of the DNR IC 50 below 100 nM, a concentration obtained in vivo during chemotherapy, could be enough for restoring clinical drug sensitivity. For the most in vitro resistant cases, the DNR IC 50 remained above 250 nM, a concentration hardly obtained during treatment.
This study provides encouraging results for using modulators in poor-risk acute leukemias: the MDR1 gene is overexpressed in more than one-third of these cases, as has previously been observed in AML, 26 gives rise to a functional protein, and could be modulated -to some extent -by GG918. The very potent in vitro efficacy of GG918 for restoring drug sensitivity of highly resistant cell lines of different origins prompts its use for the next clinical trials regarding various malignancies. ent concentrations of GG918 on rhodamine efflux of CD56 The assay developed for CD56 + cells could be used for circul-
